Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
// Xiang-Jun Tang 1,* , Xu-Yong Sun 2,* , Kuan-Ming Huang 1,* , Li Zhang 1 , Zhuo-Shun Yang 1 , Dan-Dan Zou 1 , Bin Wang 1,3 , Garth L. Warnock 4 , Long-Jun Dai 1,4 and Jie Luo 1 1 Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China 2 Guangxi Key Laboratory for Transplantation Medicine, Institute of Transplant Medicine, 303 Hospital of People’s Liberation Army, Nanning, China 3 The Biomedical Research Center, University of British Columbia, Vancouver, Canada 4 Department of Surgery, University of British Columbia, Vancouver, Canada * These authors have contributed equally to this work Correspondence to: Long-Jun Dai, email: // Jie Luo, email: // Keywords : immunotherapy, chimeric antigen receptor (CAR), exosomes, cancer therapy, extracellular vesicles Received : August 12, 2015 Accepted : October 06, 2015 Published : October 19, 2015 Abstract Chimeric antigen receptor (CAR)-based T-cell adoptive immunotherapy is a distinctively promising therapy for cancer. The engineering of CARs into T cells provides T cells with tumor-targeting capabilities and intensifies their cytotoxic activity through stimulated cell expansion and enhanced cytokine production. As a novel and potent therapeutic modality, there exists some uncontrollable processes which are the potential sources of adverse events. As an extension of this impactful modality, CAR-T cell-derived exosomes may substitute CAR-T cells to act as ultimate attackers, thereby overcoming some limitations. Exosomes retain most characteristics of parent cells and play an essential role in intercellular communications via transmitting their cargo to recipient cells. The application of CAR-T cell-derived exosomes will make this cell-based therapy more clinically controllable as it also provides a cell-free platform to diversify anticancer mediators, which responds effectively to the complexity and volatility of cancer. It is believed that the appropriate application of both cellular and exosomal platforms will make this effective treatment more practicable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 3×
“’s study, exogenous siRNA was directly loaded into DC-derived exosomes by electroporation resulting in strong mRNA and protein knockdown of targeted genes in target cells [87].”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 3×
“For example, the 4-1BB incorporated CD19 CAR-T cells can be expanded more than 1000-fold after administration in patients with chronic lymphocytic leukemia [64].”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The results from early clinical trials have revealed a very encouraging therapeutic efficacy of CAR-mediated immunotherapy in a variety of cancers including acute and chronic lymphocytic leukemia [64, 65], lymphoma [66] and neuroblastoma [67].”
BackgroundJohnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 1×
“Exosomes are nanoscale membrane vesicles (30150 nm in diameter), first described by Rose Johnstone et al in the 1980s [6].”
BackgroundLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · cited 3×
“A number of medications have been used to effectively manage CRS-induced complications, including steroids, vasopressors, IL-6 blockade, and/or supportive therapy delivered in the intensive care unit [69, 70].”
BackgroundSelf-citationGlypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880 · cited 1×
“com/oncotarget can be applied for diagnosis, predicting prognosis and monitoring the response to treatment or progression of disease, simply through examining samples from blood or other bodily fluids [38-41].”
BackgroundRegulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260 · cited 1×
“They originate from the endocytic compartment of the cells and are mainly composed of two parts, the round-shaped bilayer lipid membrane and the intravesicular content including membrane-anchored proteins [7].”
BackgroundCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730 · cited 2×
“This natural tropism emphasizes the importance of choosing the appropriate cell source for derivation of exosomes for organ-specific therapeutic modality [37].”
BackgroundGnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677 · cited 1×
“demonstrated that CM from genetically engineered MSCs cultured in vitro have an efficacy comparable to that of cell transplantation in preventing ventricular remodeling [100].”
BackgroundSelf-citationInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 1×
“Investigators even tried to include suicide genes in CARs as a safety switch to eliminate CAR-T cells if severe toxicity occurs [76, 77].”
BackgroundKochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · cited 2×
“Since the successful use of CAR-engineered T cells targeting CD19 molecules in patients with B-cell lymphoma was first reported in 2010 [4], immunotherapy has been moved from the sidelines of cancer treatment into the mainstream of modern oncology [5].”
BackgroundBiogenesis and Function of Multivesicular Bodies
Piper, R. C., & Katzmann, D. J. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123319 · Cited by 771
Exosomes: Vehicles of Intercellular Signaling, Biomarkers, and Vectors of Cell Therapy
Kourembanas, S. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071641 · Cited by 761
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex
Blanchard, N., Lankar, D., Faure, F., Regnault, A., Dumont, C., Raposo, G., & Hivroz, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3235 · Cited by 660 · cited 8×
“When target cell recognition occurs due to the interaction of T cell receptor (TCR) with the proper antigen/MHC combination the conjugate formation results in target cell death [78].”
BackgroundInfluentialExosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546 · cited 1×
“Since exosomes resemble liposomes consisting of a bi-lipid membrane and an aqueous core, they could potentially be loaded with both hydrophilic and lipophilic agents [101].”
BackgroundIsolation and Characterization of RNA-Containing Exosomes
Lässer, C., Eldh, M., & Lötvall, J. (2012) · Journal of Visualized Experiments · doi:10.3791/3037 · Cited by 509
André, F., Chaput, N., Schartz, N. E. C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2126 · Cited by 496 · cited 1×
“For example, DC-derived exosomes can deliver peptide-loaded MHC I and II complexes to other DCs and CD4+ T cells to regulate immune response [10, 104].”
BackgroundCytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99 · cited 2×
“Unlike the cell-based approach, in which therapeutic cells are able to actively migrate to the target site [85, 86], cell-free exosomes are small nanometer-sized particles and could be delivered through the blood circulation and other biological fluids as evidenced by the abundance of exosomes found in most biological…”
BackgroundSelf-citation
Cited by
Circulating Extracellular Vesicles in Human Disease
Shah, R., Patel, T., & Freedman, J. E. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1704286 · Cited by 749
The biology, function, and applications of exosomes in cancer
Liu, J., Ren, L., Li, S., Li, W., Zheng, X., Yang, Y., Fu, W., Yi, J., Wang, J., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.001 · Cited by 561
Isolation and characterization of exosomes for cancer research
Zhu, L., Sun, H.-T., Wang, S., Huang, S.-L., Zheng, Y., Wang, C.-Q., Hu, B.-Y., Qin, W., Zou, T.-T., Fu, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00987-y · Cited by 520
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Bian, D., Wu, Y., Song, G., Azizi, R., & Zamani, A. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02697-9 · Cited by 370
Metadata
- Authors
- Tang, X.-J., Sun, X.-Y., Huang, K.-M., Zhang, L., Yang, Z.-S., Zou, D.-D., Wang, B., Warnock, G. L., Dai, L.-J., & Luo, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-19
- Volume
- 6
- Issue
- 42
- Pages
- 44179-44190
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2179030446
- Cited by
- 153
- References
- 23
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.